超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

嘉和生物藥業 Genor Biopharma  
嘉和生物藥業有限公司成立于2007年12月，是一家創新驅動型生物制藥公司，主要致力于治療性單克隆抗體、Fc-融合蛋白藥物的研發與產業化。

目前公司總投資已超過2億人民幣，員工約110人。嘉和產品線現有10余個在研產品，其中3個在研產品處于臨床試驗或者臨床報批階段。嘉和擁有6000 多平米的研發中心、工藝開發中心、質量分析中心和cGMP臨床藥品生產基地，并正在規劃建設規模化的cGMP商業生產基地。

嘉和擁有一支經驗豐富并且搭配完整的資深專家組成的核心團隊，其成員專業經驗涵蓋了單抗藥物研發的各個關鍵環節。他們都來自Amgen, Abbott等國外著名生物制藥公司，均具有15~20年左右的工業界經驗。

合作是嘉和公司發展策略的關鍵組成部分。除了內部研發以外，我們還積極尋求項目引進、合作開發以及建立合資企業等機會，以豐富公司的產品線；同時，我們也積極尋求產品輸出及其他創新性合作模式的機會，以推進嘉和產品進入其他新興市場和/或歐美市場。


Founded in December 2007, Genor Biopharma is an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs.

With a total investment of about 30 million USD, Genor Biopharma now has ~ 10 products in pipeline (Three at clinical trial/IND stage), about 110 employees, and more than 6000 m2 of space including R&D lab, Process Development lab, Analytical & Quality center, and a cGMP clinical production facility. A commercial scale cGMP production facility is also under active planning.

Genor Biopharma has a highly experienced and well-integrated expert team whose expertise covers all the key steps of mAb drug research and development. They have on average 15~20 years of hand-on working experience at leading western biopharmas such as Amgen, Abbott etc.

Partnership is an intrinsic part of Genor Biopharma’s coporate strategy. Besides in-house R&D we actively seek in-licensing, co-development or JV opportunities to strengthen our pipeline. In the same time, we are also actively exploring out-licensing and other creative collaboration models to help propel Genor products into other emerging markets and/or western markets.